In a research paper published in PLOS ONE, Dario C. Altieri, president and chief executive officer, director of the Ellen and Ronald Caplan Cancer Center, and the Robert and Penny Fox Distinguished Professor at The Wistar Institute, alongside national and international collaborators, distinguish a specific gene signature indicative of mitochondrial reprogramming in tumors that correlates with poor patient outcome.
LSU Health New Orleans received a five-year, $3.1 million NIH grant to support pancreatic cancer research led by investigators in the LSU LCMC Health Cancer Center.
